3M to sell drug delivery business to Altaris Capital for $650m
US industrial conglomerate 3M has signed a cash-cum-stock deal worth around $650 million to sell substantially all of its drug delivery business to an affiliate of Altaris Capital Partners for about $650 million, as per the latest pharma acquisition news. As per the terms of the deal, the total consideration includes cash, an interest-bearing security, More...
Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC
Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) in patients who are treatment-naïve. The More...
Leucadia launches Sodium Tetradecyl Sulfate injection for varicose veins
Leucadia Pharmaceuticals, the commercial sales unit of Custopharm, has launched the FDA-approved Sodium Tetradecyl Sulfate (STS) generic injection in the US. According to Leucadia Pharmaceuticals, the regulated More...
AbbVie, Scripps Research to collaborate on developing new therapeutics
US biopharma company AbbVie has entered into a collaboration with California-based nonprofit medical research facility Scripps Research with a goal to develop new therapies for a variety of diseases, including in More...
GE Healthcare, ASLS form R&D partnership to advance 3D biofabrication
GE Healthcare Life Sciences has joined forces with Advanced Solutions Life Sciences (ASLS) for an R&D and distribution partnership with a goal to create new opportunities for regenerative tissue manufacturing More...
Astellas Pharma to acquire US gene therapy company Audentes Therapeutics
Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes Therapeutics in an all-cash deal worth about $3 billion, as per pharma acquisition More...
Janssen to acquire skin disease drug candidate bermekimab from XBiotech
Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to acquire all rights to bermekimab, an investigational compound for certain skin More...
Precision oncology company Black Diamond Therapeutics raises $85m
Black Diamond Therapeutics, a precision oncology company based in Cambridge, has raised $85 million from a Series C financing round led by Boxer Capital of the Tavistock Group. Additional new investors in the Series More...
AstraZeneca taps into Gatehouse Bio’s sRNAlytics AI platform for drug discovery
US biodata company Gatehouse Bio is joining forces with pharma giant AstraZeneca to accelerate the discovery of new drugs for respiratory and cardiovascular diseases using sRNAlytics, the former’s artificial More...
Soligenix all set to begin FLASH clinical trial for SGX301 in CTCL
US biopharma company Soligenix has wrapped up enrolling patients for its phase 3 Fluorescent Light Activated Synthetic Hypericin clinical trial (FLASH clinical trial) for SGX301 (synthetic hypericin) in cutaneous More...